Authors
Latest:
Dr. Wong on Treatment Goals in Systemic AmyloidosisSandy Wong, MD, discusses treatment goals for patients with systemic amyloidosis.
Latest:
Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLCSangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).
Latest:
Dr. Popat on the Investigation of Lurbinectedin in Second-line SCLCSanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.
Latest:
Dr. Satapathy on Recurrence in Orthotopic Liver Transplant Recipients With HCCSanjaya K. Satapathy, MD, associate professor, Transplant Hepatology Division of Surgery, Methodist University Hospital Transplant Institute, University of Tennessee Health Sciences Center, discusses preventing recurrence in orthotopic liver transplant recipients with hepatocellular carcinoma.
Latest:
Liver-Directed Therapy for Hepatic MalignanciesManagement of hepatic malignancies requires a multidisciplinary approach, and is based on the tumor burden, liver function, and PS of the patient.
Latest:
Dr. Agarwala on Entinostat for Patients with Melanoma Who Progress on PD-1/PD-L1 BlockadeSanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of entinostat for patients with melanoma who progress on a PD-1/PD-L1 blocking antibody.
Latest:
Dr. Upadhyaya Discusses Drug Development for Pediatric Patients With Brain TumorsSanthosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses drug development for pediatric patients with brain tumors.
Latest:
Dr. Sherwell-Cabello on Prognostic Impact of TILs and SILs in TNBCSantiago Sherwell-Cabello, MD, breast surgical oncology, Instituto de Enfermedades de la Mama, discusses the prognostic impact of tumor-infiltrating lymphocytes and stromal-infiltrating lymphocytes in patients with triple-negative breast cancer (TNBC).
Latest:
HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast CancerSara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.
Latest:
Treatment Advances in HR+ Breast CancerA panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.
Latest:
Future Directions in HER2-Positive Metastatic Breast CancerSara A. Hurvitz, MD, reviews therapy options for patients with HER2-positive metastatic breast cancer and comments on emerging therapeutic strategies.
Latest:
Dr. Hurvitz on the Evolution of Targeted Therapies in HER2+ Breast CancerSara A. Hurvitz, MD, discusses the evolution of targeted therapies in HER2-positive breast cancer.
Latest:
Magrolimab Plus Various Anti-Leukemia Therapies Being Studied for Efficacy in AMLMagrolimab plus combinations of various antileukemia therapies are being investigated for their efficacy in first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia.
Latest:
The Benefits for Nurses of Using Psychosocial Cancer Registry DataRegistries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.
Latest:
Sara Tinsley Discusses Quality of Life in Patients with High-Risk MDSSara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).
Latest:
A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2- Positive Metastatic Breast Cancer With Brain Metastases (BMs) from DESTINY-Breast01, -02, and -03Sara Tolaney, MD, MPH, presents an exploratory pooled analysis of efficacy and safety data of trastuzumab deruxtecan vs comparator in patients with HER2-positive metastatic breast cancer and brain metastases from DESTINY-Breast01, -02, and -03.
Latest:
Treatment Advances in HR+ Breast CancerA panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.
Latest:
Dr. McLaughlin on Lymphedema in Breast CancerSara McLaughlin, MD, professor of Surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer and addresses the complications in identifying this after her presentation at the Lynn Sage Breast Cancer Symposium.
Latest:
New Paradigm Emerging in Multiple Myeloma TherapyThe emerging treatment landscape for patients with high-risk multiple myeloma is burgeoning with new classes of drugs, novel agents, and fresh combination strategies that offer many promising and exciting options for future therapeutic approaches.
Latest:
Real-World Evidence Should Be Part of Clinical Trials in OncologyAs cancer treatment shifts from broad chemotherapy to highly personalized therapies, drug development in oncology is also evolving.
Latest:
Dr Goldberg on the Investigation of VIC-1911 With/Without Sotorasib in KRAS G12C-Mutant NSCLCSarah Goldberg, MD, MPH, discusses the design and key objectives of an ongoing phase 1a/b study of VIC-1911 as a monotherapy and in combination with sotorasib in KRAS G12C–mutant non–small cell lung cancer.
Latest:
Dr Crafton on the Use of Mirvetuximab Soravtansine in Ovarian CancerSarah Crafton, MD, discusses the potential future of antibody-drug conjugates in patients with ovarian cancer.
Latest:
Optimizing Advanced Technologies to Improve Outcomes in Esophageal CancerStudies have explored integration of chemotherapy, radiation therapy and surgery, with the suggestion that modern technologies may be changing the treatment landscape with better outcomes in esophageal cancer.
